Dronedarone hydrochloride in atrial fibrillation - horizon scanning review
NHSC
Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
NHSC. Dronedarone hydrochloride in atrial fibrillation - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2005
Authors' objectives
This study aims to assess the effectiveness of dronedarone hydrochloride in atrial fibrillation (AF).
Authors' conclusions
Dronedarone hydrochloride (SR33589B) is an antiarrhythmic drug in phase III trials to prevent recurrence of atrial fibrillation (AF) and to control ventricular rate. It is structurally similar to amiodarone but reportedly has a better adverse effect and drug interaction profile. Interim results from two unpublished, phase III, randomised, placebo-controlled trials show a significant increase in time to first recurrence of AF in patients with paroxysmal AF. A published phase II trial showed a significant increase in time to first recurrence of AF in patients with persistent AF following cardioversion.
Department of Public Health&Epidemiology, The University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom. Tel: +44 121 414 7831; Fax: +44 121 414 2269; Email: c.packer@bham.ac.uk